Antibody drug conjugate therapeutic - Axcynsis Therapeutics
Alternative Names: AT-06 ADCLatest Information Update: 26 Sep 2024
At a glance
- Originator Axcynsis Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Macrophage inhibitors; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Aug 2024 Axcynsis Therapeutics plans a phase I trial for Solid tumours (Parenteral) in 2026 (Axcynsis Therapeutics pipeline, August 2024)
- 01 Aug 2024 Preclinical trials in Solid tumours in Singapore (Parenteral) prior to August 2024 (Axcynsis Therapeutics pipeline, August 2024)